Evotec and Prolysis to Focus on Antibiotic Drugs
By Biotechdaily staff writers
Posted on 09 Dec 2002
A drug discovery collaboration to address the need for novel antibiotics has been announced by Evotec OAI AG (Hamburg, Germany) and Prolysis Ltd. (Oxford, UK).Posted on 09 Dec 2002
Prolysis has been focused on the discovery and development of new antibiotics through the use of bacterial molecular genetics based on patented technology invented by Professor Jeff Errington of the University of Oxford (UK). Prolysis targets essential cellular processes not inhibited by current antibiotics. Evotec will apply its biologic, medicinal, and computational chemistry skills to design and synthesize compounds against selected Prolysis targets. Evotec will optimize the drug-like properties of these compounds by using its ADME/Tox platform. The company will receive fees for services as well as an equity stake in Prolysis.
"With this strategic collaboration, we have once more demonstrated the attractiveness of our business model to offer innovative deal structures to target-oriented biotech companies, creating substantial value for both companies in a long-term relationship,” said Joern Aldag, president and CEO of Evotec.
Related Links:
Evotec
Prolysis